

## References

S-163

1. Jagsi R, Hawley S, Katz S, et al. Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer. *JAMA Surgery*[serial online]. 2017;152(3):274-282. Available from: MEDLINE Complete, Ipswich, MA. Accessed July 10, 2018.
2. Nash R, Goodman M, Jemal A, et al. State Variation in the Receipt of a Contralateral Prophylactic Mastectomy Among Women Who Received a Diagnosis of Invasive Unilateral Early-Stage Breast Cancer in the United States, 2004-2012. *JAMA Surgery*[serial online]. 2017;152(7):648-657. Available from: MEDLINE Complete, Ipswich, MA. Accessed July 10, 2018.
3. Jakub JW, Peled AW, Gray RJ, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population With BRCA Mutations: A multi-institutional study. 2018;153(2):123-129.
4. Li X, You R, Wang X, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. *Clin Cancer Res*. Aug 01 2016;22(15):3971-3981. PMID 26979395.
5. Ludwig KK, Neuner J, Butler A, et al. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. *Am J Surg*. Oct 2016;212(4):660-669.
6. Wong SM, Freedman RA, Sagara Y, et al. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. *Ann Surg*. Mar 2017;265(3):581-589.
7. Chagpar A. Contralateral prophylactic mastectomy. In: Vora S (Ed). UpToDate. Waltham, Mass:UpToDate. 2017. [www.uptodate.com](http://www.uptodate.com).
8. Schott S, Vetter L, Heil J, et al. Women at familial risk of breast cancer electing for prophylactic mastectomy: frequencies, procedures, and decision-making characteristics. *Arch of Gyn and Obst* [serial online]. 2017;295(6):1451-1458. Available from: MEDLINE Complete, Ipswich, MA.
9. InterQual® Level of Care Criteria. 2018. Acute Care Adult. McKesson Health Solutions
10. Honold F, Camus M. Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women's BRCA carriers. *Medwave*. 2018;18(4):e7161.
11. Jakub JW, Peled AW, Gray RJ, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population With BRCA Mutations: A multi-institutional study. 2018;153(2):123-129.

12. Hegde J, Wang X, Attai D, Di Nome M, et al. Assessing the effect of lifetime contralateral breast cancer risk on the selection of contralateral prophylactic mastectomy for unilateral breast cancer. *Clinical Breast Cancer*. 2018;18:E205-E218.
13. Nash R, Goodman M, Jemal A, et al. State Variation in the Receipt of a Contralateral Prophylactic Mastectomy Among Women Who Received a Diagnosis of Invasive Unilateral Early-Stage Breast Cancer in the United States, 2004-2012. *JAMA Surgery* [serial online]. 2017;152(7):648-657. Available from: MEDLINE Complete, Ipswich, MA.
14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High- Risk Assessment: Breast and Ovarian. Version 3.2019.
15. Teoh V, Tasoulis M, and Gui G. Contralateral Prophylactic Mastectomy in women with unilateral breast cancer who are genetic carriers, have a strong family history or are just young at presentation. *Cancers*. 2020;12:140.
16. Bouchard-Fortier N, Baxter N, Sutradha R, Fernandes K, Camacho X, Graham P, and Quan M. Contralateral prophylactic mastectomy in young women with breast cancer: a population-based analysis of predictive factors and clinical impact. *Curr Oncol*. 2018;6:e562-e568.